Recombinant human interleukin 11 (IL-11) reduces the frequency and load of bacteremia associated with chemotherapy, according to the results of a randomized, double-blind, placebo-controlled trial reported in the Jan. 25 issue of The Lancet.
“The administration of IL-11 reduces bacteremia, predominantly of gastrointestinal origin, in patients with hematological malignant disease undergoing chemotherapy,” lead author Michael E. Ellis, from the United Arab Emirates in Al Ain, says in a news release.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!